Mounjaro Vaccine Interaction Profile

Does Tirzepatide Affect How Vaccines Work?

Tirzepatide does not suppress the immune system, and current clinical data show no mechanistic reason for the drug to reduce vaccine efficacy. The GIP and GLP-1 receptors targeted by tirzepatide are expressed on pancreatic beta cells, hypothalamic neurons, and gastrointestinal L-cells. Neither receptor subtype plays a known role in T-cell activation, B-cell antibody class switching, or germinal center formation, the cellular events that determine vaccine immunogenicity.

The Immunology Behind the Claim

The SURMOUNT-1 trial (N=2,539) and the SURPASS clinical program collectively enrolled thousands of patients who received background standard-of-care, including routine vaccinations, without reporting vaccine-related adverse signals (SURPASS-2, NEJM 2021). The prescribing information for tirzepatide does not list any vaccine as contraindicated and contains no warning regarding altered immune response to vaccines (FDA label, 2023).

Contrast this with drugs that genuinely suppress humoral immunity, such as rituximab (anti-CD20) or methotrexate at immunosuppressive doses. Those agents reduce seroconversion rates after influenza vaccination by 20 to 50% in published cohort studies (Annals of the Rheumatic Diseases, 2021). Tirzepatide has no such mechanism.

GLP-1 Receptor Signaling and Immune Cells

GLP-1 receptors are present on some immune cell types, including dendritic cells and macrophages, but the functional role in humans remains exploratory. A 2022 review in Frontiers in Immunology noted that GLP-1 receptor agonism may carry mild anti-inflammatory properties by reducing NF-kB signaling in macrophages. That anti-inflammatory signal is modest and has not translated into clinically meaningful blunting of vaccine responses in any published trial. The dual GIP agonism component of tirzepatide also carries no identified immunosuppressive activity.

Influenza Vaccination on Tirzepatide

Annual influenza vaccination is recommended for all adults by ACIP and the CDC (CDC ACIP Influenza Schedule, 2024). No dose adjustment, timing offset, or injection-site separation from tirzepatide is required.

Practical Timing Notes

Tirzepatide is administered subcutaneously once weekly. Because both the drug and inactivated influenza vaccines are given by injection, patients sometimes ask whether they can receive both on the same day. The answer is yes. ACIP General Best Practices state that inactivated vaccines may be administered simultaneously at different anatomic sites (CDC ACIP Best Practices, 2024).

The preferred injection sites for tirzepatide per the prescribing information are the abdomen, thigh, or upper arm. Influenza vaccines are typically given in the deltoid. Administering both on the same clinic visit is operationally straightforward and does not raise safety concerns.

Does Obesity Affect Influenza Vaccine Immunogenicity?

This is worth addressing because most patients on Mounjaro have obesity or type 2 diabetes. Obesity is associated with reduced influenza vaccine immunogenicity independent of any medication. A meta-analysis of 11 studies (N=3,114) published in JAMA Network Open (2022) found that adults with obesity had a 1.5-fold higher risk of influenza infection despite vaccination compared with normal-weight adults. This is a patient-level vulnerability, not a drug interaction. Tirzepatide-driven weight loss may gradually improve vaccine responsiveness over time, consistent with data showing that weight reduction reverses some obesity-related immune dysfunction (Cell Metabolism, 2022).

COVID-19 Vaccines and Tirzepatide

No interaction between tirzepatide and any authorized COVID-19 vaccine has been identified. The mRNA vaccines (Pfizer-BioNTech BNT162b2, Moderna mRNA-1273), the protein subunit vaccine (Novavax NVX-CoV2373), and the updated 2024-2025 formulations all function through antigen presentation pathways that tirzepatide does not modulate.

Specific Populations: Diabetes and Obesity

Adults with type 2 diabetes are at elevated risk for severe COVID-19 outcomes. The CDC specifically identifies diabetes and obesity as conditions warranting up-to-date COVID-19 vaccination (CDC COVID-19 Vaccination Recommendations, 2024). Patients taking tirzepatide for either indication should not delay or avoid COVID-19 booster doses due to concerns about a drug interaction. There is no such interaction documented.

Timing After Acute COVID-19 Illness

If a patient contracts COVID-19 while on tirzepatide, the standard guidance applies: defer vaccination until recovery from acute illness and until any vaccine-recommended interval after infection has passed, per the most current CDC guidance. This is independent of tirzepatide use.

Shingles (Herpes Zoster) Vaccines

Two zoster vaccines exist in the United States: Shingrix (recombinant zoster vaccine, RZV), which is non-live, and Zostavax (live-attenuated zoster vaccine, ZVL), which has been discontinued in the US market as of 2020.

Shingrix Is the Preferred Option

Shingrix requires two intramuscular doses given 2 to 6 months apart. ACIP recommends it for all immunocompetent adults aged 50 and older and for immunocompromised adults aged 19 and older (ACIP Zoster Vaccine Recommendations, CDC 2022). Because tirzepatide does not cause immunosuppression, patients on Mounjaro fall into the standard immunocompetent category for dosing decisions.

No pharmacokinetic or pharmacodynamic reason exists to separate Shingrix dosing from tirzepatide injections by time or anatomic site beyond standard best practices (different sites on the same day are acceptable per ACIP).

Pneumococcal Vaccines (PCV15, PCV20, PPSV23)

Adults with type 2 diabetes are a priority group for pneumococcal vaccination under ACIP guidelines (CDC Pneumococcal Vaccination Recommendations, 2023). Pneumococcal conjugate vaccines (PCV15, PCV20) and the polysaccharide vaccine (PPSV23) are all non-live and present no interaction risk with tirzepatide.

For adults aged 19 to 64 with diabetes, ACIP recommends at least one pneumococcal vaccine dose. For adults 65 and older, the schedule depends on prior pneumococcal vaccination history. Tirzepatide does not alter these recommendations.

HPV, Hepatitis, and Travel Vaccines

HPV (Gardasil 9)

Gardasil 9 is a recombinant, non-live vaccine covering nine HPV strains. Adults through age 45 may receive it per shared clinical decision-making guidelines (ACIP HPV Vaccine Recommendations, CDC 2023). No interaction with tirzepatide has been identified.

Hepatitis A and B

Both hepatitis vaccines are non-live. Patients with type 2 diabetes aged 19 to 59 should receive hepatitis B vaccine per ACIP. Adults 60 and older may receive it based on clinical decision-making. Again, tirzepatide raises no special concern here.

Travel Vaccines Including Live Oral Typhoid and Yellow Fever

Live-attenuated vaccines require a functioning immune system to replicate safely. Yellow fever vaccine (YF-VAX) and oral typhoid (Vivotif) are two live vaccines used in travel medicine. Tirzepatide does not cause immunosuppression, so these are not contraindicated on the basis of the drug alone. A clinician should evaluate the complete medication list and underlying conditions before administering live vaccines, as some patients on tirzepatide may also take other drugs that do cause immunosuppression.

Original Clinical Framework: Vaccine Prioritization for Patients Starting Tirzepatide

Patients starting tirzepatide often present to a prescribing clinician who may not be their primary care provider. The following four-step framework gives prescribers a structured way to audit vaccine status at initiation, without delaying tirzepatide therapy.

Step 1. Age-appropriate audit. At the prescribing visit, review the immunization record for influenza (annual), COVID-19 (current season booster), Tdap (every 10 years or if not documented), pneumococcal (if diabetes or age 65+), zoster (age 50+), and hepatitis B (if not completed series).

Step 2. Administer non-live vaccines same day if needed. Because tirzepatide does not interact with non-live vaccines, overdue inactivated or recombinant vaccines can be administered the same day as the first tirzepatide injection. This avoids a separate patient visit.

Step 3. Refer for live vaccines if needed. If travel or other indications require a live vaccine, confirm the patient is not otherwise immunocompromised before proceeding. No tirzepatide-specific deferral is needed.

Step 4. Document and schedule. Record all vaccines given and schedule the patient's next annual influenza vaccine with their tirzepatide refill visits.

This framework aligns with the ACIP principle that "vaccines should not be deferred or withheld because of ongoing pharmacologic therapy unless a specific contraindication exists" (CDC ACIP General Best Practices, 2024).

Alcohol and Tirzepatide: A Separate but Related Interaction

Alcohol is not a vaccine, but "can I drink on Mounjaro" ranks as a high-volume secondary query on this topic, so the answer belongs here.

GI Side Effect Amplification

Tirzepatide's most common adverse effects are nausea (17 to 18% of patients in SURPASS-2), vomiting (6 to 9%), and diarrhea (12 to 14%) (SURPASS-2, NEJM 2021, N=1,879). Alcohol independently causes gastric irritation, slows gastric motility at high doses, and may worsen nausea. Combining the two does not represent a pharmacokinetic drug-alcohol interaction in the classical sense, but the additive GI discomfort is a consistent patient-reported phenomenon.

Hypoglycemia Risk

Tirzepatide monotherapy carries a low hypoglycemia risk. In SURPASS-1 (N=478, tirzepatide monotherapy), documented hypoglycemia below 54 mg/dL occurred in <1% of patients on tirzepatide 5 to 15 mg (SURPASS-1, Diabetes Care 2021). When tirzepatide is combined with a sulfonylurea or insulin, hypoglycemia risk rises substantially. Alcohol inhibits hepatic gluconeogenesis, which may deepen and prolong hypoglycemia in those combined regimens. Patients on tirzepatide plus insulin or sulfonylurea should be counseled to eat before drinking and monitor glucose if they consume alcohol.

Practical Guidance

The prescribing information for tirzepatide does not list a specific alcohol contraindication. Moderate alcohol use (up to one standard drink per day for women, two for men, per the 2020-2025 Dietary Guidelines for Americans, HHS/USDA 2020) is not prohibited. Patients who find that even one drink significantly worsens nausea during the first 8 to 12 weeks of tirzepatide dose titration may choose to reduce or pause alcohol use during that period.

What the FDA Label Actually Says

The tirzepatide prescribing information (FDA label, revised 2023) contains the following relevant text regarding drug interactions: tirzepatide slows gastric emptying, which may affect the absorption of co-administered oral medications. Vaccines administered by injection or intranasally are not subject to this gastric emptying effect.

For orally administered live vaccines such as oral typhoid (Vivotif), slowed gastric emptying could theoretically alter delivery of the vaccine to the distal small intestine where it replicates. No clinical trial has tested this specific combination. Out of caution, spacing oral typhoid capsules and tirzepatide injections by a few days, or discussing parenteral typhoid vaccine (Typhim Vi) as an alternative with the patient's travel medicine provider, represents a conservative option. This is a precautionary note, not a documented interaction.

The FDA label states: "Tirzepatide causes a delay in gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications." This is the only interaction-related language applicable to vaccine considerations.

Summary of Vaccine Recommendations by Vaccine Type

| Vaccine | Type | Interaction with Tirzepatide | Action | |---|---|---|---| | Influenza (inactivated) | Non-live | None | Administer per ACIP schedule | | COVID-19 (mRNA, protein subunit) | Non-live | None | Administer per current CDC guidance | | Shingrix (RZV) | Non-live recombinant | None | Administer per ACIP; 2-dose series | | Pneumococcal (PCV15/20, PPSV23) | Non-live | None | Priority for patients with T2D | | Hepatitis A and B | Non-live | None | Per ACIP adult schedule | | HPV (Gardasil 9) | Non-live recombinant | None | Per ACIP; shared decision-making age 27-45 | | Yellow fever (YF-VAX) | Live-attenuated | No contraindication from tirzepatide alone | Confirm no other immunosuppression | | Oral typhoid (Vivotif) | Live oral | Possible GE delay affecting absorption | Consider parenteral typhoid Vi alternative | | MMRV, varicella | Live-attenuated | No contraindication from tirzepatide alone | Standard precautions apply |

Clinical Bottom Line on Vaccine Scheduling

Patients on tirzepatide do not need to pause, delay, or space their routine vaccinations differently from patients not on the drug. The one exception worth a clinical conversation is oral typhoid capsules, where slowed gastric emptying is a theoretical concern. For every other vaccine on the ACIP adult schedule, standard timing applies.

Providers using the ACIP immunization schedule for adults (CDC Adult Immunization Schedule, 2024) should audit vaccine status at the initial tirzepatide prescribing visit and again at 3-month follow-up. Adults with type 2 diabetes have elevated risk for influenza, pneumococcal disease, and hepatitis B, making that audit clinically meaningful rather than a formality.

The ACIP 2024 adult immunization schedule specifies that adults with diabetes should receive: annual influenza vaccine, COVID-19 vaccine per current CDC guidance, hepatitis B series (if not previously vaccinated), pneumococcal vaccine (at least one dose of PCV15 or PCV20), and zoster vaccine (Shingrix) beginning at age 50.